{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:15:51Z","timestamp":1757618151558,"version":"3.44.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In the DREAMM-2 trial, belantamab mafodotin (belamaf) monotherapy demonstrated clinical activity and a manageable safety profile in pretreated patients with relapsed\/refractory multiple myeloma (RRMM). Real-world evidence on this patient population is scarce. This study describes real-world baseline characteristics, ocular events, and time-to-event outcomes of patients with RRMM before, during, and after belamaf treatment between August 1, 2020, and March 31, 2023, in Germany based on anonymized health insurance claims data. In the overall cohort (<jats:italic>N<\/jats:italic>\u2009=\u200931), the median age was 66 years and all patients had received several MM therapies prior to treatment with belamaf. Of the patients included in the pre-belamaf (<jats:italic>n<\/jats:italic>\u2009=\u200931), belamaf (<jats:italic>n<\/jats:italic>\u2009=\u200931), and post-belamaf (<jats:italic>n<\/jats:italic>\u2009=\u200922) treatment periods, 10 (32.3%), 16 (51.6%), and 15 (68.2%) had at least one recorded ophthalmological visit, respectively. Keratitis was the most frequent among ocular diagnoses of interest across all three study periods. During the belamaf treatment period, seven (22.6%) patients had one or more incident ocular diagnoses of interest, the most frequent being corneal-related events. In the overall cohort, the real-world progression-free survival and overall survival were 4.3 months (95% confidence interval [CI] 2.4\u20137.7) and 12.3 months (95% CI 6.9\u2013not evaluable), respectively. Our data emphasize the importance of ocular supportive care during belamaf treatment in real-world clinical practice. Our findings also highlight that RRMM remains an aggressive disease with a poor prognosis.<\/jats:p>","DOI":"10.1007\/s00277-025-06427-6","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T03:50:04Z","timestamp":1748663404000},"page":"3289-3298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world characteristics and outcomes of patients with multiple myeloma treated with belantamab mafodotin: a German claims data study"],"prefix":"10.1007","volume":"104","author":[{"given":"Jaime","family":"Luna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"d\u2019Estrube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Lehne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Wellmann-Pichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Mevius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Dornig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"issue":"3","key":"6427_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hajek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U, EHA Guidelines Committee, ESMO Guidelines Committee (2021) Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(dagger). Ann Oncol 32(3):309\u2013322. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.014","journal-title":"Ann Oncol"},{"key":"6427_CR2","unstructured":"Zentrum f\u00fcr Krebsregisterdaten (2023) Multiple myeloma. https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Multiples%20Myelom\/multiples_myelom_node.html. Accessed September 16, 2024"},{"issue":"1","key":"6427_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-021-01109-y","volume":"14","author":"CT Su","year":"2021","unstructured":"Su CT, Ye JC (2021) Emerging therapies for relapsed\/refractory multiple myeloma: CAR-T and beyond. J Hematol Oncol 14(1):115. https:\/\/doi.org\/10.1186\/s13045-021-01109-y","journal-title":"J Hematol Oncol"},{"issue":"2","key":"6427_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Raab MS, Schoen P, Cavo M (2016) Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 175(2):252\u2013264. https:\/\/doi.org\/10.1111\/bjh.14213","journal-title":"Br J Haematol"},{"issue":"2","key":"6427_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortum KM, Rodriguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD (2020) Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 21(2):207\u2013221. https:\/\/doi.org\/10.1016\/S1470-2045(19)30788-0","journal-title":"Lancet Oncol"},{"issue":"23","key":"6427_CR6","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1002\/cncr.34987","volume":"129","author":"AK Nooka","year":"2023","unstructured":"Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, Abdallah AO, Trudel S, Chari A, Libby EN, Chaudhry M, Hultcrantz M, Kortum KM, Popat R, Sborov D, Hakim S, Lewis E, Gorsh B, Bhushan B, McKeown A, Gupta I, Opalinska J, Richardson PG, Lonial S (2023) Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer 129(23):3746\u20133760. https:\/\/doi.org\/10.1002\/cncr.34987","journal-title":"Cancer"},{"issue":"5","key":"6427_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balari AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV (2024) Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 391(5):393\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2405090","journal-title":"N Engl J Med"},{"key":"6427_CR8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Morris K, Pompilus F, Phillips-Jones A, Zhou XL, Fulci G, Sule N, Kremer BE, Opalinska J, Mateos MV, Trudel S, Dreamm-7 Investigators (2024) Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med 391:408\u2013421. https:\/\/doi.org\/10.1056\/NEJMoa2403407","journal-title":"N Engl J Med"},{"key":"6427_CR9","unstructured":"European Medicines Agency (2024) Blenrep: EPAR - product information. Accessed November 2024"},{"key":"6427_CR10","doi-asserted-by":"publisher","first-page":"678634","DOI":"10.3389\/fonc.2021.678634","volume":"11","author":"A Wahab","year":"2021","unstructured":"Wahab A, Rafae A, Mushtaq K, Masood A, Ehsan H, Khakwani M, Khan A (2021) Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. Front Oncol 11:678634. https:\/\/doi.org\/10.3389\/fonc.2021.678634","journal-title":"Front Oncol"},{"issue":"21","key":"6427_CR11","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-22-0618","volume":"28","author":"AC Baines","year":"2022","unstructured":"Baines AC, Ershler R, Kanapuru B, Xu Q, Shen G, Li L, Ma L, Okusanya OO, Simpson NE, Nguyen W, Theoret MR, Pazdur R, Gormley NJ (2022) FDA approval summary: belantamab mafodotin for patients with relapsed or refractory multiple myeloma. Clin Cancer Res 28(21):4629\u20134633. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0618","journal-title":"Clin Cancer Res"},{"key":"6427_CR12","unstructured":"Ministry of Health Pflegeleistungen zum Nachschlagen (2024) Accessed November 10, 2024 https:\/\/www.bundesgesundheitsministerium.de\/service\/publikationen\/details\/pflegeleistungen-zum-nachschlagen"},{"key":"6427_CR13","doi-asserted-by":"publisher","first-page":"e19507","DOI":"10.1200\/JCO.2024.42.16_suppl.e19507","volume":"42","author":"M Patel","year":"2024","unstructured":"Patel M, Locke SC, Falvey C, Troy JD, Herring KW, Bolgioni-Smith A, Doherty A, Elcock CH, Iadeluca LL, LeBlancTW (2024) e19507: Real-world analysis of belantamab mafodotin (belamaf): care patterns in relapsed\/ refractory multiple myeloma. J Clin Oncol 42:e19507 (16_suppl)","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"6427_CR14","doi-asserted-by":"publisher","first-page":"e20009f20004","DOI":"10.1097\/01.HS9.0000975232.20009.f4","volume":"7","author":"MKD Hultcrantz","year":"2023","unstructured":"Hultcrantz M, KleinmanD, Vij R, Escalante F, Delforge M, Kotowsky N, Bitetti J, Boytsov N, Camadoo-O\u2019Byrne L, Happ LP, Rohman M, Germain G, Duh MS, Lalibert\u00e9 F, Mahendran M, Urosevic A, Lee HC (2023) PB2114: belantamab mafodotin for relapsed\/refractory multiple myeloma: A real-world observational study. Hemasphere 7(Suppl):e20009f20004. https:\/\/doi.org\/10.1097\/01.HS9.0000975232.20009.f4","journal-title":"Hemasphere"},{"key":"6427_CR15","doi-asserted-by":"publisher","unstructured":"Hultcrantz M, Kleinman D, Vij, Escalante F, Kotowsky N, Bitetti J, Mackay C, Boytsov N, Camadoo-O'Byrne L, Germain G, Duh MS, Lalibert\u00e9 F, Mahendran M, Urosevic A, Lee HC (2022) Belantamab mafodotin (belamaf) for relapsed\/refractory multiple myeloma (RRMM): a real-world observational study. Blood 140 (Supplement 1):10124\u201310126. https:\/\/doi.org\/10.1182\/blood-2022-164929","DOI":"10.1182\/blood-2022-164929"},{"issue":"12","key":"6427_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41408-021-00592-3","volume":"11","author":"I Vaxman","year":"2021","unstructured":"Vaxman I, Abeykoon J, Dispenzieri A, Kumar SK, Buadi F, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Reeder C, Sher T, Hayman S, Kourelis T, Warsame R, Muchtar E, Leung N, Go R, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Kristen M, Kapoor P, Gertz MA (2021) Real-life data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo clinic experience. Blood Cancer J 11(12):196. https:\/\/doi.org\/10.1038\/s41408-021-00592-3","journal-title":"Blood Cancer J"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06427-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06427-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06427-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:31:52Z","timestamp":1757176312000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06427-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6427"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06427-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JL and ML are employees of Cytel, contracted by GSK to conduct the study. Td\u2019E, AJ, and BWP are employed by GSK and hold financial equities in GSK. AM is an employee of IPAM, contracted by Cytel to support the data analyses. SD is an employee of AOK PLUS and has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}